| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 03/27/2001 | US6207169 Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
| 03/27/2001 | US6207162 AspS from Chlamydia trachomatis |
| 03/27/2001 | US6207160 aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies |
| 03/27/2001 | US6207158 Parasitic helminth macrophage migration inhibitory factor proteins, nucleic acid molecules, and uses thereof |
| 03/27/2001 | US6207156 Specific antibodies and antibody fragments |
| 03/27/2001 | US6207155 Antibody which reduces concentration of eosinophil |
| 03/27/2001 | US6207153 Antigen binding polypeptide |
| 03/27/2001 | US6207152 Anticancer agent |
| 03/27/2001 | CA2135200C Canine coronavirus s gene and uses therefor |
| 03/27/2001 | CA2076540C Recombinant antibodies specific for tnf-.alpha. |
| 03/27/2001 | CA2065860C Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix |
| 03/27/2001 | CA1341208C Proteins with factor viii activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| 03/23/2001 | CA2309372A1 Use of antibodies against the nef protein for decreasing the chemotaxis which is induced by retrovirus-infected astrocytes |
| 03/22/2001 | WO2001020038A1 Novel cell cycle checkpoint genes and proteins encoded thereby |
| 03/22/2001 | WO2001020033A1 Methods for selecting prostate cancer treatments and treating prostate cancer |
| 03/22/2001 | WO2001020026A2 POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
| 03/22/2001 | WO2001020025A2 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/22/2001 | WO2001020004A2 Protein phosphatase and kinase proteins |
| 03/22/2001 | WO2001020000A1 Nucleic acid which is obtained from tetrahymena and which codes for a delta-6-desaturase, the production thereof and use |
| 03/22/2001 | WO2001019997A2 Basb128 polypeptide and polynucleotide from moxarella catarrhalis |
| 03/22/2001 | WO2001019996A1 Moraxella catarrhalis antigen, corresponding gene and uses thereof |
| 03/22/2001 | WO2001019992A2 FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES |
| 03/22/2001 | WO2001019983A1 Human g-protein coupled receptor |
| 03/22/2001 | WO2001019967A1 Human inflammatory breast carcinoma xenograft capable of lymphovascular invasion and methods for its use |
| 03/22/2001 | WO2001019955A2 Lysosomal targeting pathway enzymes |
| 03/22/2001 | WO2001019871A2 Delivery system for antidandruff agent |
| 03/22/2001 | WO2001019869A1 Dendritic cell membrane protein cire |
| 03/22/2001 | WO2001019866A1 Dipeptidyl peptidases |
| 03/22/2001 | WO2001019863A1 Preparation of highly pure toxin fragments |
| 03/22/2001 | WO2001019862A2 Polypeptides from moraxella (branhamella) catarrhalis |
| 03/22/2001 | WO2001019861A2 Apo-2 receptor antibodies |
| 03/22/2001 | WO2001019860A2 Proteins associated with cell differentiation |
| 03/22/2001 | WO2001019856A2 Secreted human proteins, polynucleotides encoding them and methods of using the same |
| 03/22/2001 | WO2001019850A2 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | WO2001019846A1 Transgenically produced fusion proteins |
| 03/22/2001 | WO2001019842A1 Subunit optimized fusion proteins |
| 03/22/2001 | WO2001019398A1 Method for treatment of symptoms of central nervous system disorders |
| 03/22/2001 | WO2001019397A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | WO2001019396A1 Therapies for chronic renal failure using one or more integrin antagonists |
| 03/22/2001 | WO2001019395A1 Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis |
| 03/22/2001 | WO2001019394A2 Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds |
| 03/22/2001 | WO2001019388A1 Medicament containing contactinhibin and medicament containing antibodies directed against contactinhibin |
| 03/22/2001 | WO2001019373A2 Methods and compositions for modulating responsiveness to corticosteroids |
| 03/22/2001 | WO2001019335A2 Composition to be administered through mucous membrane |
| 03/22/2001 | WO2001009332A3 Immunogenic polypeptides derived from moraxella catarrhalis and uses thereof |
| 03/22/2001 | WO2001000811A3 17867, a novel human aminopeptidase |
| 03/22/2001 | WO2000073323A3 Adam polynucleotides and polypeptides |
| 03/22/2001 | WO2000060066A8 Protein-protein from s. cerevisiae and methods of using same |
| 03/22/2001 | WO2000059943A3 MONOCLONAL ANTIBODIES AGAINST HUMAN PROTEIN Mcm3, PROCESS FOR THEIR PRODUCTION, AND THEIR USE |
| 03/22/2001 | WO2000029443A9 Contraceptive antibody vaccines |
| 03/22/2001 | WO1999063936A8 Novel therapeutic agents that modulate endothelin receptors |
| 03/22/2001 | WO1999058678A9 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 03/22/2001 | WO1999050661A3 Method and test kit for detecting central nervous system tissue in meat products |
| 03/22/2001 | CA2385234A1 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | CA2384920A1 Moraxella catarrhalis antigen, corresponding gene and uses thereof |
| 03/22/2001 | CA2384876A1 Composition to be administered through mucous membrane |
| 03/22/2001 | CA2384766A1 Subunit optimized fusion proteins |
| 03/22/2001 | CA2384762A1 Apo-2 receptor antibodies |
| 03/22/2001 | CA2384749A1 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 03/22/2001 | CA2384733A1 Methods and compositions utilizing rad51 |
| 03/22/2001 | CA2384660A1 Factor ix/factor ixa antibodies and antibody derivatives |
| 03/22/2001 | CA2384324A1 Proteins associated with cell differentiation |
| 03/22/2001 | CA2384135A1 Dipeptidyl peptidases |
| 03/22/2001 | CA2383927A1 Protein phosphatase and kinase proteins |
| 03/22/2001 | CA2383292A1 Basb128 polypeptide and polynucleotide from moxarella catarrhalis |
| 03/22/2001 | CA2383217A1 Lysosomal targeting pathway enzymes |
| 03/22/2001 | CA2383177A1 Human g-protein coupled receptor |
| 03/22/2001 | CA2383081A1 Polypeptides from moraxella (branhamella) catarrhalis |
| 03/22/2001 | CA2382725A1 Transgenically produced fusion proteins |
| 03/22/2001 | CA2381066A1 Polymorphisms in the human hpxr gene and their use in diagnostic and therapeutic applications |
| 03/22/2001 | CA2379541A1 Polymorphisms in the human cyp3a4 and cyp3a7 genes and their use in diagnostic and therapeutic applications |
| 03/22/2001 | CA2344155A1 Methods for selecting prostate cancer treatments and treating prostate cancer |
| 03/21/2001 | EP1085093A2 Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof |
| 03/21/2001 | EP1085088A1 Monoclonal antibodies and method for assaying fdp |
| 03/21/2001 | EP1084274A1 Acrp30r2, a homolog of acrp30 (30 kd adipocyte complement-related protein) |
| 03/21/2001 | EP1084273A1 Probes used for genetic profiling |
| 03/21/2001 | EP1084259A1 Corin, a serine protease |
| 03/21/2001 | EP1084255A1 Tankyrase, a trf1 binding protein |
| 03/21/2001 | EP1084254A1 Transgenic plants presenting a modified inulin producing profile |
| 03/21/2001 | EP1084252A1 Nucleic acid vaccines for prevention of flavivirus infection |
| 03/21/2001 | EP1084249A2 Transgenic plant cells expressing a recombinant plant e2f peptide |
| 03/21/2001 | EP1084247A1 Disulfide core polypeptides |
| 03/21/2001 | EP1084246A2 Biological material for preparing pharmaceutical compositions for treating mammals |
| 03/21/2001 | EP1084245A1 Human receptor tyrosine kinase |
| 03/21/2001 | EP1084244A1 Tnfr-like protein with death domain |
| 03/21/2001 | EP1084243A2 Protein for regulating apoptosis |
| 03/21/2001 | EP1084242A2 Phagocytic assay method |
| 03/21/2001 | EP1084241A1 G-protein coupled receptor, named 2871 receptor |
| 03/21/2001 | EP1084239A1 Polymorphic markers of prostate carcinoma tumor antigen-1 (pcta-1) |
| 03/21/2001 | EP1084228A1 GENES CODING FOR TOMATO beta-GALACTOSIDASE POLYPEPTIDES |
| 03/21/2001 | EP1084227A1 Compositions and methods for use in affecting hematopoietic stem cell populations in mammals |
| 03/21/2001 | EP1084147A1 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 03/21/2001 | EP1084146A2 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| 03/21/2001 | EP1084145A2 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use thereof for diagnosis and therapy of tumors and diseases associated with angiogenesis |
| 03/21/2001 | EP1084142A1 Gpr35a receptor |
| 03/21/2001 | EP1084141A1 nrdF |
| 03/21/2001 | EP1084136A1 Separation of protein monomers from aggregates by use of ion-exchange chromatography |
| 03/21/2001 | EP1084135A1 The human kidney specific gene kk86 |
| 03/21/2001 | EP1083928A1 Method of inhibiting angiogenesis and tumor growth and preventing tumor growth and metastases |
| 03/21/2001 | EP1083921A1 Novel leukotriene receptor antagonists and their uses |